Previous studies have shown that the inhibitory effect of some drugs on laryngeal cancer is closely related to the mitogen‐activated protein kinases (MAPK) pathway.6, 13 Therefore, we examined the three signaling molecules involved in the MAPK pathway, including c‐Jun N‐terminal kinase (JNK), extracellular regulated kinases 1/2 (ERK1/2), and p38. The gene discussed is MAPK3; the disease is laryngeal carcinoma.